Section 232 Pharmaceutical Tariffs: September 29 Go-Live and Heading Selection

Section 232 pharmaceutical tariffs have been in force since July 31, 2026, but only for 17 named companies. For every other importer of record the duty starts on September 29, 2026. Proclamation 11020, published at 91 FR 18183 on April 9, 2026, and implemented through CBP CSMS #69395344, built a rate structure where two facts decide what an entry pays: the status of the company that makes or sells the drug, and the patent or exclusivity status of the specific product. Country of origin and the HTS number still matter, but on their own they no longer tell a trade team what to declare.

That design catches large importers off guard because most duty models key off origin and classification. A branded manufacturer importing the same molecule from the same plant can face 100%, 15%, 0% or a phased 20% depending on which Chapter 99 heading the entry qualifies for. This guide covers the heading map, the two start dates, the product-level patent line, the specialty product rules published on September 23, 2026, and what the entry file needs before the first shipment that lands after September 29. For the general mechanics of the statute, see our overview of Section 232 tariffs. Status reflects the Federal Register and CBP guidance as of September 23, 2026.

Two Start Dates: Annex III Companies on July 31, Everyone Else on September 29

The most common misreading of Proclamation 11020 treats Annex III as a product list with a late effective date. It is the reverse. Annex III names 17 companies whose treatment started on July 31, 2026. Every company not named there, and not otherwise exempt, starts paying on September 29, 2026.

Thirteen of the 17 Annex III companies also hold Annex II agreements and enter at 0% under 9903.04.65 through January 20, 2029; the other four (GlaxoSmithKline and ViiV, Johnson & Johnson, Pfizer and Regeneron) have paid their applicable rate since July 31.

The practical question for a trade team is not only which list its own company appears on. Importers of record that are distributors, CDMOs or 3PL-held inventory owners often import products made by several manufacturers. Each manufacturer’s status travels with the product, so one purchase order can mix Annex II, Annex III and unnamed-company lines. Mapping that before September 29 is the first readiness task.

The 9903.04 Headings and What Decides Which One Applies

CBP implements the program through Chapter 99 headings 9903.04.60 through 9903.04.69, with 9903.04.70 created by a notice published on September 23, 2026 and effective for entries from September 29, 2026. Each heading corresponds to a rate and a qualifying condition. The table lists every heading in the range as described in the proclamation, CSMS #69395344 and the September 23 notice.

Selecting the heading is a legal determination, not a data-entry step. The 15% rate for the EU, Japan, Korea, Switzerland and Liechtenstein under 9903.04.62 is inclusive, meaning the cap already absorbs the ordinary duty rather than being added to it. The UK rate under 9903.04.63 dropped to 0% from July 31, 2026 through a separate Federal Register action, FR doc 2026-15799. The onshoring heading 9903.04.64 carries 20% and rises to 100% on April 2, 2030; CBP noted that no company was yet eligible for it. Every entry needs a documented reason for the heading chosen, because a post-entry review will ask for it.

Patented, Unpatented and Generic: Where the Product-Level Line Falls

The default 100% rate under 9903.04.60 attaches to patented drugs. Generics enter at 0% under 9903.04.67. That split makes patent and exclusivity status a classification input, and most importers do not hold it in their product master. For small-molecule drugs the reference point is the FDA Orange Book; for biologics it is the Purple Book. Each SKU needs a recorded status, the source consulted and the date checked, because patent and exclusivity positions change and the entry has to reflect the status on the date of entry.

The Federal Register notice published on September 23, 2026 (FR doc 2026-19498) changes the generic definition for entries from September 29, 2026. Unpatented animal health products then count as generics, which moves a group of veterinary imports from exposure to 0%. The same notice removes five HTS codes from Annex IV. Importers that screened their catalog before September 23 should rerun the screen against the revised lists rather than rely on the earlier result.

Active pharmaceutical ingredients and bulk intermediates need their own review. API distributors are among the importers most exposed to the program, yet whether a given API or intermediate falls inside the covered HTS lines depends on its classification and the annex lists, not on how the buyer uses it. APIs and key starting materials of patented drugs are covered when they fall in the listed HTS classification lines; excipients and inactive ingredients are not. From September 29, articles in the listed lines that are neither patented nor generic pharmaceutical articles go under 9903.04.69 at 0%.

Company Status, Onshoring Plans and the September 23 Specialty Product Rules

Company status is the second axis. Annex II membership comes from MFN pricing arrangements, and Annex III membership was fixed by name. For unnamed companies the realistic levers are the onshoring heading, the specialty product rate and product-level headings such as generics or R&D. None of these is automatic. Each has to be claimed, supported and defended entry by entry.

FR doc 2026-19498 defines the specialty products that qualify for a 0% rate under clause 3(d) of Proclamation 11020 (orphan-only drugs, nuclear medicines, plasma-derived therapies, fertility drugs, cell and gene therapies, antibody drug conjugates, CBRN countermeasures and animal health products). They qualify either as products of one of 19 listed jurisdictions, including the EU, Japan, Korea, Switzerland, the UK and India, or through a Commerce approval for an urgent U.S. health need, requested by email to BIS. The notice also created 9903.04.70 at 0% for clinical-trial, research-and-development and other non-commercial material, effective for entries from September 29, 2026. Clinical-supply teams that previously shipped investigational product under ordinary entries should route those shipments to the new heading and keep the protocol documentation with the entry. Prototype and test material can also be reviewed against 9817.85.01.

Urgent-need requests to BIS should be built as evidence files rather than letters. That means product identification down to the HTS line, the manufacturer’s status, the patent position, the clinical or supply rationale and the volumes involved. A request that arrives without that structure is slower to review, and until an approval is granted the entry pays the rate its heading carries. Our Section 232 consulting team prepares these files alongside the heading map so the two stay consistent.

Patented pharmaceutical articles entered under 9903.04.60 to 9903.04.66 are exempt from the Section 301 forced labor tariff from July 31, 2026. Generics and other lines are not covered by that exemption and need their own check. Importers who also bring in non-pharmaceutical goods should keep that exemption scoped correctly; our guide to Section 301 forced labor tariffs covers how that duty applies elsewhere.

Drawback, FTZ and Bonded Storage: Questions to Settle Before the First Entry

Drawback is available. Clause (10) of Proclamation 11020 and CSMS #69395344 confirm that the pharmaceutical Section 232 duties are drawback eligible, unlike the semiconductor action. At a 100% rate, drawback on re-exported product is significant, and the claim depends on import and export records kept from the first entry.

Covered products admitted to a foreign-trade zone must take privileged foreign status under clause (13), so a zone helps with inventory control, weekly entry and handling but does not avoid the duty on goods consumed in the United States. The time to plan both is before the goods arrive, because zone status elections and drawback records cannot be rebuilt afterward. Our duty drawback services team can scope a claim for re-exported product, and our FTZ consulting group can model zone admission options.

Goods already in a customs bonded warehouse raise the same timing question. The rate applies on withdrawal for consumption, so withdrawals before and after September 29 can be treated differently. Confirm the applicable rule for your inventory before scheduling withdrawals around the date.

What the Entry File Needs Before the First Post-September 29 Shipment

The entry file for a pharmaceutical line after September 29 carries more than an invoice and a classification. The table below is the working checklist we use. It sits on top of the existing FDA drug entry requirements, including the registration and drug listing data transmitted with the entry, which do not change because of the tariff. Manufacturers that are not yet set up for FDA should start with FDA registration, because a tariff-ready entry that fails FDA review still does not release.

A Readiness Plan for the Week Before Go-Live

The work that matters in the final days before September 29 is sequencing. First, split the SKU list by manufacturer status so the Annex II, Annex III and unnamed-company lines are visible. Second, attach patent and exclusivity status to every unnamed-company SKU, starting with the highest-value lines. Third, assign a proposed 9903.04 heading and a written rationale to each line. Fourth, identify lines that could qualify for 9903.04.70 or the specialty product rate and start those files. Fifth, rerun the landed cost for each product family so commercial teams price from the post-September 29 number rather than the current one.

Importers who already paid since July 31 because a supplier sits in Annex III should also review those entries. A heading chosen quickly in August may not match the heading descriptions in CSMS #69395344, and post-summary corrections are easier while the entries are still unliquidated.

Frequently Asked Questions